mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response
Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1111/jgh.16512 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Toshifumi Tada und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Sustained Virologic Response, alpha-Fetoproteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Background and Aim The study aims to develop a novel predictive model including the fibrosis (FIB)‐3 index for hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C virus (HCV) who achieved sustained virological response (SVR) with direct‐acting antiviral (DAA) therapy.
Methods
This study included 2529 patients in whom HCV was eradicated with DAA therapy. The after DAA recommendation for surveillance (ADRES) score, which is based on sex, FIB‐4 index, and α‐fetoprotein, was used to predict HCC development. We developed a modified ADRES (mADRES) score, in which the FIB‐4 index was replaced by the FIB‐3 index, and evaluated its usefulness in predicting HCC development compared with the ADRES score.
Results
In the training set ( n = 1770), multivariate analysis with Cox proportional hazards modeling showed that male sex (hazard ratio [HR], 2.11; 95% confidence interval [CI], 1.48–3.01), FIB‐3 index (HR, 1.36; 95% CI, 1.28–1.45), and α‐fetoprotein (HR, 1.05; 95% CI, 1.03–1.07) are independently associated with HCC development. The incidence of HCC differed significantly by ADRES or mADRES score in multiple comparisons. Univariate Cox proportional hazards models showed that compared with the mADRES score 0 group, the HR for HCC development was 2.07 (95% CI, 1.02–4.19) for the mADRES score 1 group, 11.37 (95% CI, 5.80–22.27) for the mADRES score 2 group, and 21.95 (95% CI, 10.17–47.38) for the mADRES score 3 group. Similar results were obtained for mADRES score but not for ADRES score in the validation set ( n = 759).
Conclusion
The mADRES score is useful for predicting HCC development after SVR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
- Department of Nursing, Gifu Kyoritsu University, Gifu, Japan.
- Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
- Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
- Department of Internal Medicine, Himeji St. Mary's Hospital, Himeji, Japan.
ORCID-Profile: Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Kazuya Kariyama, Hideko Ohama, Hidenori Toyoda
Zitieren
APA
Tada, T., Kumada, T., Hiraoka, A., Kariyama, K., Yasuda, S., Tada, F., Ohama, H., Nouso, K., Matono, T., Nakamura, S., Toyoda, H., & Real‐life Practice Experts for HCC (RELPEC) Study Group (2024). mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16512
Vancouver
Tada T, Kumada T, Hiraoka A, Kariyama K, Yasuda S, Tada F, et al. mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16512
BibTeX
@article{Tada2024,
author = {Tada, Toshifumi and Kumada, Takashi and Hiraoka, Atsushi and Kariyama, Kazuya and Yasuda, Satoshi and Tada, Fujimasa and Ohama, Hideko and Nouso, Kazuhiro and Matono, Tomomitsu and Nakamura, Shinichiro and Toyoda, Hidenori and Real‐life Practice Experts for HCC (RELPEC) Study Group, Real‐life Practice Experts for HCC (RELPEC) Study Group},
title = {mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1111/jgh.16512}
}
EUVIMED